Fludarabine News
Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA
Xanthus Pharmaceuticals, Inc., a privately-held oncology and autoimmune disease drug development company, today announced that its New Drug Application (NDA) for fludarabine phosphate oral tablets (oral fludarabine) was accepted...
Protherics and Advancell start Acadra(TM) clinical study in B-cell chronic lymphocytic leukaemia
Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, and its co-development partner, Advancell s.l. ("Advancell"), today announce that the first patient...
Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG
Xanthus Embarks on Path for Commercialization in the United States
Nipent®, Cytoxan® and Rituxan® Effective for Untreated Poor Risk CLL
Researchers from Ohio State University and the Mayo Clinic have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan (cyclophosphamide) and Rituxan (rituximab) (PCR) demonstrates high activity in...
Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Randomized Trial to Evaluate Fludarabine and Rituximab with or without Genasense in Previously Untreated Patients